- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 58 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August... ► Artikel lesen | |
| Mi | Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate | 2 | Benzinga.com | ||
| Mi | Vor Bio: RemeGen Achieves Primary Endpoint In Phase 3 Study In China Evaluating Telitacicept | 3 | RTTNews | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | Vor Biopharma: Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor | 182 | GlobeNewswire (Europe) | Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3... ► Artikel lesen | |
| 12.08. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 10 | SEC Filings | ||
| 07.08. | Vor Bio hires commercial chief, reuniting ex-Sarepta colleagues in freshly rebuilt C-suite | 2 | FiercePharma | ||
| 04.08. | Vor Biopharma: Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer | 172 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment... ► Artikel lesen | |
| 22.07. | Vor Biopharma Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 21.07. | Vor Bio appoints two industry veterans to its board of directors | 1 | Investing.com | ||
| 21.07. | Vor Biopharma: Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 18.07. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 195 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective... ► Artikel lesen | |
| 17.07. | Vor Biopharma: Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer | 161 | GlobeNewswire (Europe) | Dr. Zuraw led clinical development of telitacicept across MG, Sjögren's, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience... ► Artikel lesen | |
| 10.07. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.07. | Vor Bio beruft Branchenveteran Sandy Mahatme zum Finanz- und Geschäftsvorstand | 3 | Investing.com Deutsch | ||
| 10.07. | Vor Bio appoints Sandy Mahatme as CFO and CBO | 1 | Investing.com | ||
| 10.07. | Vor Bio appoints Sandy Mahatme as CFO | 1 | Seeking Alpha | ||
| 10.07. | Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer | 717 | GlobeNewswire (Europe) | Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company's transformation and growth in autoimmune disease CAMBRIDGE, Mass.,... ► Artikel lesen | |
| 01.07. | Vor Biopharma: Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 190 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective... ► Artikel lesen | |
| 30.06. | Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market | 3 | Benzinga.com | ||
| 30.06. | Vor Biopharma stock rating upgraded to Buy by H.C. Wainwright on telitacicept deal | 4 | Investing.com |
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,314 | -1,28 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2025 Results and Business Updates | Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,039 | +0,51 % | SOL Global Investments Corp.: SOL Global Appoints Hex Trust as Strategic Web3 Partner to Execute Institutional Digital Asset Strategy | Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") on 23 July, 2025, appointed Hex Trust, a leading... ► Artikel lesen | |
| TRINITY BIOTECH | 1,560 | 0,00 % | Trinity Biotech plc: Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara Preeclampsia Testing Service | DUBLIN, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,990 | -2,54 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates | First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 17,890 | 0,00 % | Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Other Big Stocks Moving Higher On Tuesday | ||
| OVID THERAPEUTICS | 0,820 | +3,80 % | Ovid Therapeutics GAAP EPS of -$0.06, revenue of $6.3M | ||
| EQUILLIUM | 1,150 | +1,95 % | Equillium: Up To $50 Million Financing Raised To Advance EQ504 | ||
| 4D MOLECULAR THERAPEUTICS | 7,280 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 13,330 | 0,00 % | Regencell Bioscience Holdings Limited Announces Forward Stock Split | HONG KONG, June 2, 2025 - Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the "Company"), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the... ► Artikel lesen | |
| GENERATION BIO | 6,640 | 0,00 % | Generation Bio stock price target raised to $10 from $9 at Canaccord | ||
| CABALETTA BIO | 1,770 | 0,00 % | Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update | - Registrational cohort enrollment in RESET-Myositis trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis - - Five disease-specific cohorts fully enrolled... ► Artikel lesen | |
| LONGEVERON | 0,809 | 0,00 % | Longeveron Announces Second Quarter 2025 Financial Results and Provides Business Update | Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS... ► Artikel lesen | |
| PROKIDNEY | 2,535 | 0,00 % | ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type... ► Artikel lesen | |
| BOLT PROJECTS | 7,020 | 0,00 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| ATHIRA PHARMA | 0,383 | 0,00 % | Athira Pharma, Inc.: Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates | Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing... ► Artikel lesen |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.